Camel-IDS will run a phase 1b/2 trial of its lead radiopharmaceutical in HER2-positive breast cancer that has spread to the brain.

The deal sees I-Mab agree to take the immuno-oncology candidate up to clinical proof of concept.

Dermavant hires Zavodnick as CEO; Bayer VP to lead Matoke Pharma; and Genentech I-O leader Wei Lin will head up Nektar's oncology work.

Tocagen has named Lori Kunkel as its acting CMO after the departure of Asha Das, who is leaving because of “immediate personal matters.”

In this week's EuroBiotech Report, uniQure clears a hemophilia B test, Themis scraps its planned IPO, Boehringer backs Amal and more. 

A combination of Novartis' Farydak and Incuron's experimental CBL0137 made neuroblastoma disappear In mice.

AbbVie and Mission Therapeutics inked an R&D pact focused on deubiquitylating enzymes in Alzheimer’s and Parkinson’s disease.

In our EuroBiotech roundup this week, Mission pens pact with AbbVie, NorthSea posts NASH data and Redx unveils fibrosis drug.

In a collaboration worth up to $300 million or more, Boehringer Ingelheim tapped Epizyme to help research two regulators of genes linked to cancer.

Arena’s run of positive news continues, with a massive $800 million upfront deal with United for pulmonary arterial hypertension drug ralinepag.